Novartis-Intas Ranibizumab Settlement Sets Liability For Breach
This article was originally published in Scrip
Executive Summary
Novartis and Intas Pharmaceuticals Ltd have reached an out-of-court settlement pertaining to their dispute concerning ranibizumab.
You may also be interested in...
Cadila-Hetero Slugfest Over The 'Hep' Tag
Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.